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Recurrent chromosome breakpoints in tumour cells may point to cancer genes, but not many have been molecularly characterised.
We have used multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) on breast tumour cell lines to identify regions
of chromosome break created by inversions, duplications, insertions and translocations on chromosomes 1, 5, 8, 12 and 17. We
delineate a total of 136 regions of break, some of them occurring with high frequency. We further describe two examples of dual-
colour FISH characterisation of breakpoints, which target the 1p36 and 5p11–12 regions. Both breaks involve genes whose function
is unknown to date. The mbanding-FISH strategy constitutes an efficient first step in the search for potential cancer genes.
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Many loci that contribute to mammary oncogenesis remain
probably to be discovered. Only a handful of genes have been
demonstrated to have a direct role in mammary oncogenesis after
alteration. At the chromosomal level, amplifications, transloca-
tions and deletions point to the existence of a potential cancer gene
in an affected region. Genes such as ERBB2 and CCND1, which
encode a tyrosine kinase receptor and a G1 cyclin, respectively, are
likely the selected oncogenes of the 17q12 and 11q13 amplification,
respectively. For other amplification regions, such as the 8p12 and
20q13 regions, and for deletions, the identity of the cancer genes
remains uncertain. The characterisation of translocations has
provided additional cancer gene candidates, such as FHIT
(Popovici et al, 2002), NTRK3 and ETV6 (Tognon et al, 2002;
our unpublished observations), BCAS (Ba ¨rlund et al, 2002) and
NRG1 (Wang et al, 1999; Ade ´laı ¨de et al, 2003; Huang et al, 2004)
genes. Given the number of recurrent chromosomal breaks
observed in breast cancer (http://cgap.nci.nih.gov/Chromosomes/
RecurrentAberrations), this line of research might become more
fruitful than the search for deletions through loss of heterozygosity
data, which has been rather disappointing (Devilee et al, 2001).
Although the mechanisms and consequences of translocations are
not as clear as for those found in hemopathies and sarcomas, the
existence of recurrent events suggests a role for the genes located
at the breakpoints and provides a relatively easy way to discover
more cancer genes.
A major limitation of this approach, however, is the difficulty to
obtain reliable informative data on chromosomes of breast
tumours. Technologies such as chromosome painting, spectral
karyotyping (SKY) and multiplex- or multicolour-fluorescence in
situ hybridisation (M-FISH) (Schro ¨ck et al, 1996; Speicher et al,
1996) can overcome the limitations of conventional cytogenetical
methods in the characterisation of complex chromosome altera-
tions observed in cancers. They allow the simultaneous visualisa-
tion of all human chromosomes in different pseudocolours and a
better characterisation of the rearrangements. However, intrachro-
mosomal rearrangements or the origin of abnormal chromosomal
segments cannot be defined with these techniques. To overcome
these limitations, different multicolour-banding techniques in-
cluding mbanding-FISH have been developed (Mu ¨ller et al, 1997,
1998; Chudoba et al, 1999; Liehr et al, 2002a,b; Kakazu et al, 2003).
They can be performed with combinations of well-defined
subregional probes (Mu ¨ller et al, 2004). They can reveal
aberrations not visible by other methods, and consequently
facilitate the molecular identification of targeted genes. Obtaining
good metaphase cells in breast tumours is still difficult but cell
lines may, in a first step, be used to evaluate the usefulness of the
approach.
We have used mbanding-FISH to search for regions of recurrent
alterations in breast tumour cell lines on five chromosomes. We
have identified several such regions. We show that mbanding-FISH
is a powerful method to identify rapidly regions of chromosomal
breaks. We report two examples of further characterisation of
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sbreakpoints, which target the 1p36 and 5p11–12 regions. This
technology should constitute an efficient first step in the search for
potential cancer genes.
MATERIAL AND METHODS
Tumour cell lines
In all, 20 established breast tumour cell lines were used. They were
as follows: Br-Ca-MZ-01 (Mo ¨bus et al, 1998), BT-474, CAMA-1,
HCC1937 (Tomlinson et al, 1998), MCF-7, MCF-10F, MDA-MB-
157, MDA-MB-175, MDA-MB-231, MDA-MB-361, MDA-MB-453,
MDA-MB-468, SK-BR-3, UACC-812, ZR-75-1 (ATCC, Rock-
ville, MD, USA), SUM-44, SUM-52, SUM-149, SUM-185 (Forozan
et al, 1999; http://www.cancer.med.umich.edu/breast_cell/clines/
clines.html) and IPC-BC-116. We established the latter cell line
from an inflammatory carcinoma, after informed consent of the
patient; the tumoral karyotype was established and displayed a
t(1;6)(p36;p21) translocation as sole abnormality. All lines are
derived from carcinomas except MCF-10F, which is derived from a
fibroadenoma. The cells were grown using the recommended
culture conditions, while IPC-BC-116 was grown in DMEM/Ham
F12 medium (1/1) supplemented with 10% FBS, 10mgml
 1 Insulin,
1mgml
 1 hydrocortisone and 10ngml
 1 EGF.
Mbanding-FISH
The harvesting of cells, fixation and preparation of metaphase
spreads for chromosome banding analysis and FISH were carried
out from cytogenetic pellets of cultured cell lines according to
protocols described in Courtay-Cahen et al (2000). Mbanding-
FISH, a high-resolution multicolour-banding technique that
provides precise information on intrachromosomal rearrange-
ments and exact breakpoint mapping, was performed on chromo-
some metaphases cell lines (Table 1) with probe chromosome 1-,
5-, 8-, 12- and 17-mband cocktails, according to the protocol
recommended by Metasystems (Chudoba et al, 1999) and as
described previously (Popovici et al, 2002). The commercial probe
mband cocktail derives from microdissected region-specific partial
chromosome paints (PCP). Each PCP is labelled using a unique
fluorochrome combination and partially overlaps with the
neighbouring one.
The specific chromosome-mband cocktail was denatured and
hybridised on treated and denatured metaphase chromosomes,
according to the manufacturer’s protocol. After hybridisation,
chromosomes were washed with 50% formamide/2 SSC and
2 SSC at 421C. The excitation/emission spectra of the fluor-
ochromes are equivalent to FITC, Spectrum Oranget, TexasRed
s
and DEAC (diethylamino-coumarin (www.metasystems.de)). For
chromosome 1-, 5-, 8- and 12-mband cocktail probes, an
additional labelling was carried out using biotin, which is detected
by Streptavidin-Cyt5 (B-tect).
After counterstaining with 4,6-diamidino-2-phenylindole, the
images were analysed with a microscope (DMRXA, Leica Micro-
syste `mes, Marseille, France), captured with a CCD camera, filtered
and processed with ISIS software (In Situ Imaging Systems,
Metasystems Hard- und Software GmbH, Altlussheim, Germany)
(described in www.metasystems.de). The resulting fluorescence
intensity pattern along the chromosome axis shows a continuous
change of colour ratios. Pseudocolours can be assigned to
chromosome sections of similar colour ratios giving rise to a
reproducible banding pattern that does not depend on chromo-
some condensation (Chudoba et al, 1999).
A region of breakpoints was defined by comparison between
the abnormal colour spectrum of a derivative chromosome and
the normal profile of the corresponding nonaltered chromo-
some; a disruption of colour-banding pattern defines a region of
break. Amplifications by duplication or triplication were defined
on the basis of duplicate or triplicate of at least two colour
sections observed on the abnormal colour spectrum and
pseudocolour profile of a derivative chromosome. At least 10
metaphases exhibiting the same derivative chromosomes were
studied, and mbanding colour profiles were analysed for each
derivative.
FISH analysis
To delineate the t(1;6)(p36;p21) and t(5;12)(p12;p11) events, and
identify the potential genes involved, dual colour FISH analysis
was carried out using labelled DNA of BAC clones as probes as
described previously (Ade ´laı ¨de et al, 2003) on IPC-BC-116 and
UACC-812 breast tumour cell lines, respectively.
To refine rapidly the 1p36 breakpoint in the t(1;6)(p36;p21)
rearrangement, the following BAC clone set covering this region
was selected with variable genomic distance between clones: tel-
RP11-164A22 (AC055792; chr1:14,996,330-15,182,825), RP11-
430L17 (AL358794; chr1:16,386,491-16,511,439), RP11-473A10
(AL358593; chr1:17,656,749-17,799,202), RP11-99F3 (AC020587;
chr1:18,111,224-18,284,657), RP11-294O9 (AC026576; chr1:19,390,
941-19,574,586), RP11-97J18 (AL391598; chr1:19,804,646-19,980,
341), RP11-200J11 (AC022786; chr1:20,673,314-20,851,807) and
RP11-487E1 (AL627311; chr1:21,041,056-21,210,231)-cen. To refine
the 5p12 breakpoint, we selected BAC clones included in the
region, close to, or contained in the 876F7 YAC clone previously
described spanning the breakpoint at 5p12 (Popovici et al, 2002):
tel-RP11-453A8 (AC027488; chr5:40,533,761-40,705,000), RP11-30
F7 (AC016332; chr5:41,237,134-41,386,355), RP11-9G14 (included
in NT_006576 and mapped by FHCRC lab; chr5:41,319,672-41,
319,970), RP11-190J8 (AC021600; chr5:41,384,203-41,536,708),
RP11-184C11 (AC025649; chr5:41,472,703-41,639,760)-cen. DNA
from BAC clones were purified, labelled and used as probes in
combination with centromeric probes specific for chromosome
6 (revealed in green, FITC) or digoxigenin-labelled centromeric
probe specific for chromosome 12 (revealed in red, TRITC). All
BAC clones were obtained from the BACPAC resource (Children’s
Hospital Oakland - BACPAC Resources, Oakland, CA, USA). Image
analysis was carried out as described in the previous section.
Table 1 Breast tumour cell lines analysed by mbanding-FISH
Cell lines Chr1 Chr5 Chr8 Chr12 Chr17
BrCa-MZ-01 X
BT-474 X
CAMA-1 X X X X
HCC1937 X X X
IPC-BC-116 X
MCF-7 X X
MCF-10F X X
MDA-MB-157 X X X
MDA-MB-175 X
MDA-MB-231 X X X
MDA-MB-361 X
MDA-MB-453 X
MDA-MB-468 X X
SK-BR-3 X X X
SUM-44 X X
SUM-52 X X
SUM-149 X X X
SUM-185 X X
UACC-812 X X X X
ZR-75-1 X X X X
Total 11 10 9 7 8
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Regional localisation of chromosomal breakpoints on
chromosomes 1, 5, 8, 12 and 17 in breast tumour cell lines
We chose to study five chromosomes by mbanding-FISH, that is, 1,
5, 8, 12 and 17. The reasons of our choice were the following: these
chromosomes have different sizes and are affected with various
frequencies in breast cancer (Kyto ¨la ¨ et al, 2000; Teixeira et al,
2002) (Table 1). Examples of mbanding-FISH are illustrated in
Figure 1 showing breakpoints on der(1)t(1;14)(p34;q?), i5(p),
der(12)t(1;12)(?;p13.3), der(12;16)(q10;?q10) and der(11)(t(11;17)
(?;q21.3–22) derivative chromosomes observed in MDA-MB-231
(Figure 1A), MDA-MB-157 (Figures 1B and 1C) and ZR-75-1
(Figure 1D), respectively. A region of breakpoint was defined by
comparison between the abnormal colour spectrum of a derivative
chromosome and the normal profile of the corresponding
nonaltered chromosome. The regions are indicated on the
corresponding ideograms (Figures 1A–D, bottom part). For each
of the cell line studied, one to several derivative chromosomes could
be observed. Comprehensive results in agreement to ISCN (1995)
are described as supplementary data (Supplementary Table 1). For
economical reasons, when previous experiments (e.g. with M-FISH)
had demonstrated integrity of one or more of the five selected
chromosomes in a cell line, this cell line was not studied with the
respective mbanding probe. This explains why not all cell lines were
systematically investigated with the five chromosome probes.
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Figure 1 Examples of mbanding-FISH in breast tumour cell lines. MDA-MB-231 (A), MDA-MB-157 (B and C) and ZR-75-1 (D) were analysed by FISH
with specific mband cocktail probes for chromosome 1 (A), 5 (B), 12 (C) and 17 (D), respectively. M-FISH images of normal (save for chromosome 12 in
MDA-MB-157 (C)), and derivative chromosomes 1, 5, 12 and 17 previously characterised in these cell lines (Popovici et al, 2002) are shown on the left hand
of the corresponding mband images (pseudocolour profile) defined by colour spectra (on the right). Regional locations of breakpoints targeting
der(1)t(1;14)(p34;q?) (A), I(5)(p10) (B), der(12)t(1;12)(?;p13.3) (C upper part), der(12;16)(q10;?q10) (C middle part) and der(11)(t(11;17)(?;q21.3–22)
(D) present in MDA-MB-231 (A), MDA-MB-157 (B and C) and ZR-75-1 (D), respectively, were assigned by comparison with the normal profile. They are
indicated by arrowheads on the corresponding ideograms (bottom part), which exhibit on their right hand the sequence of microdissected region-specific
PCP labelled using a unique fluorochrome combination defining then the normal colour spectrum. Each PCP was labelled and partly overlaps with the
neighbouring one.
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sAll breakpoints were located, and their positions are shown in
Figure 2A. After considering all derivatives for each cell line, a total
of 136 breakpoints were described. They were distributed as
follows: 47, 29, 28, 18 and 14 on chromosome 1, 5, 8, 12 and 17,
respectively. They were located on 4 (chromosome 17) to 11
(chromosome 1) regions per chromosome (Figure 2A) (Supple-
mentary Table 1 and Figure 2A). The same region of breakpoint
could be found in one (e.g. 12q13) to seven (1q21) cell lines. The
same chromosome was affected in eight to 11 cell lines (Table 1).
The regions with more than three breakpoints are referenced in
Table 2. For each of them, a breakpoint incidence (BI) was defined
for each chromosome as the ratio of the number of events found in
this region and the total number of breakpoints observed along the
given chromosome (47, 29, 28, 18 and 14 for chromosome 1, 5, 8,
12 and 17, respectively). For each chromosome, a recurrence index
(RI) was defined as the ratio of the number of affected cell lines
and the total number of tested cell lines. The product BI RI
allowed to point to breakpoints presenting both high breakpoint
incidence and high recurrence (Table 2).
Definition of altered regions on each chromosome
There were 11 altered regions on chromosome 1. The pericen-
tromeric region (p12–p22.1 to q11–q21.2) was the site of the most
frequent alterations, involving derivatives in about 80% of the
analysed cell lines. Mbanding-FISH also allowed the delineation of
deletions on both arms of chromosome 1, while amplifications by
duplication or triplication were found only on the q arm.
We defined six altered regions on chromosome 5. The most
frequent were at 5p11–p13.2 and 5q23.2–q31.1, and affected 70%
of the tested cell lines. These regions were located centromeric to
FRA5E (5p14) and close to or within FRA5C, respectively; breaks
may thus be the consequence of a particular fragility of these
regions. Four frequently altered regions were found on chromosome
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Figure 2 (A) Regional distribution of breakpoints in breast tumour cell lines. From mbanding-FISH analysis on breast tumour cell lines, a total of 136
breakpoints were described (Supplementary Table 1). Each coloured circle corresponds to a cell line as defined in the inset in upper right corner. These
circles are positioned on ideograms of normal 1, 5, 8, 12 and 17 chromosomes in the region affected by breakpoints characterised in cell lines derivatives
reported in the supplementary table. Each coloured circle represents a breakpoint observed in one derivative. The occurrence order of coloured circles
follows the order of breakpoints characterised in the corresponding cell lines reported in the supplementary table, for example, two circles with the same
colour on the same region mean that this region is involved in two different derivatives present in the same cell line. Black arrows show 1p36 and 5p12
breakpoints of the t(1;6)(p36;p21) and t(5;12)(p12;p11) present in IPC-BC-116 and UACC-812, respectively. (B and C) Dual-colour FISH refinement of
two target regions. Dual-colour FISH experiment carried out on metaphase chromosomes from IPC-BC-116 (B) with digoxigenin-labelled DNA of RP11-
164A22 (revealed in red, TRITC) in combination with biotinylated DNA of RP11-99F3 and centromeric probe specific for the chromosome 6 (revealed in
green, FITC). The telomeric position of RP11-164A22 allowed the identification of normal chromosome 1 and derivative chromosome 6. The concomitant
presence of RP11-99F3 on both derivatives and on chromosome 1 suggested that this clone spans the 1p36 breakpoint. Similarly, dual-colour FISH
experiment carried out on metaphase chromosomes from UACC-812 (C) using biotinylated DNA of RP11-190J8 BAC (revealed in green, FITC) and
digoxigenin-labelled centromeric probe specific for chromosome 12 (revealed in red, TRITC) shows that RP11-190J8 spans the 5p12 breakpoint.
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s8: 8p11–p12, 8q10–q21.1, 8q22.1–q23 and 8q24.1-qter. We
identified two frequently altered regions on chromosome 12:
12p11–p12 and 12q24.1-qter. Finally, we identified only one
frequently altered region on chromosome 17, at 17q21.3–q22.
Breakpoint characterisation
To confirm that mbanding-FISH is a useful means of screening for
chromosomal breaks, we selected two of the potential breakpoints,
one in the low incidence range and the second in the high
incidence range. The 1p36 and 5p12 breakpoints of the
t(1;6)(p36;p21) and t(5;12)(p12;p11) present in IPC-BC-116 and
UACC-812 cell lines, respectively, were studied by dual-colour
FISH (Figures 2B–C, respectively). Figure 2B shows the results of a
dual-colour FISH experiment carried out on metaphase chromo-
somes from IPC-BC-116 with digoxigenin-labelled DNA of RP11-
164A22 (revealed in red, TRITC) in combination with biotinylated
DNA of RP11-99F3 and centromeric probe specific for chromo-
some 6 (revealed in green, FITC). The telomeric position of RP11-
164A22 allowed the identification of normal chromosome 1 and
derivative chromosome 6. The concomitant presence of RP11-99F3
on both derivatives and on chromosome 1 suggested that this
clone spans the 1p36 breakpoint. The RP11-99F3 BAC clone
(AC020587) contains the MGC15730 gene (hypothetical protein
MGC15730) covering 270kb. This gene has 10 exons and produces
two variant transcripts by alternative splicing (UCSC Genome
Browser on Human May 2004 Assembly is based on NCBI Build 35
(National Center for Biotechnology Information, US National
Library of Medicine 8600 Rockville Pike, Bethesda, MD, USA)).
The biological function of the corresponding putative proteins is
not known.
The t(5;12)(p13;p11) translocation present in UACC-812 targets
the most frequently altered region of chromosome 5 (Figure 2A).
The FISH analysis using biotinylated DNA of RP11-190J8 BAC
clone (AC021600) in combination with the digoxigenin-labelled
centromeric probe for chromosome 12 allowed the characterisa-
tion of the breakpoint (Figure 2C). The RP11-190J8 BAC clone
contains the 50 part of the LOC345557 gene (XM_293875.4) (similar
to RIKEN cDNA B130016O10 gene) expressed as two uncharac-
terised sequences BX648329.1 (7601bp) and AK127142 (2432bp).
Currently, the biological function of the corresponding putative
proteins is not known. Using the SMART software (http://
smart.embl-heidelberg.de/smart/show_motifs.pl), a phospholipase
C catalytic domain (noted ‘PLCXc’) was detected in the XP_293875
protein sequence associated to BX648329.1 mRNA. A link was also
found with AK127142, which is probably generated by alternative
splicing.
DISCUSSION
Multicolour-banding approach: towards a better definition
of chromosomal rearrangements in breast cancers
The progress of FISH technologies based on chromosome painting,
SKY and multiplex-FISH or multicolour-FISH (M-FISH) (Schro ¨ck
et al, 1996; Speicher et al, 1996) has overcome the limitations of
conventional cytogenetic methods in the characterisation of
complex chromosome alterations observed in cancers. It offers a
simultaneous visualisation of all human chromosomes in different
pseudocolours, and allows a better characterisation of the
rearrangements. However, the definition of chromosomal abnorm-
alities such as intrachromosomal changes or abnormal chromo-
somal segments could not be approached with these techniques.
To overcome these limitations, different multicolour-banding
techniques have been developed such as: (i) mbanding-FISH (also
called multicolour banding) (Chudoba et al, 1999; Liehr et al,
2002a,b), which is a modification of M-FISH, (ii) a chromosome
bar code technique (Mu ¨ller et al, 1997), (iii) a crossspecies colour-
banding technique called Rx-FISH (Mu ¨ller et al, 1998) and (iv) a
spectral colour banding known as SCAN (Kakazu et al, 2003).
These approaches have different levels of banding resolution
(Kakazu et al, 2003). Very recently, the resolution of discernable
bars was increased to 100bars per haploid chromosome set by
including human chromosome-specific probes and more well-
defined subregional probes (Mu ¨ller et al, 2004). The analysis of
chromosomal alterations using these techniques could reveal new
aberrations not visible by other methods, and consequently
facilitate the molecular characterisation of target genes.
Comparison of our results with literature data
Our findings correlate well with what is known for chromosome 1.
This chromosome is one of the most frequently affected in breast
cancers (Dutrillaux et al, 1990; Bie `che et al, 1993; Pandis et al,
1995; Teixeira et al, 2002; http://cgap.nci.nih.gov/Chromosomes/
RecurrentAberrations). Analyses of breast tumours have estab-
lished a frequency of breaks as follows: 1p36 (6.5%), 1p22 (6.1%),
1p13 (5.9%), 1q10 (24%), 1q11–12 (7%), 1q21 (9.1%), 1q25 (5%)
and 1q42 (5.9%) (Teixeira et al, 2002). Frequent allelic imbalances
have been found at 1p36 (11%), 1q42–44 (13–14%) and
amplification is commonly observed at 1q21. The presence of at
least four potential tumour suppressor genes (TSG), at 1p13, 1p22,
1p31 and 1p34-pter, has been suggested (see for a review, Bie `che
et al, 1999). Unbalanced translocations affecting chromosome 1
frequently lead to segmental losses, which could target TSG, while
oncogenes could be activated by intrachromosomal amplification
(essentially on 1q) or by promoting gene fusion.
As opposed to chromosome 1, aberrations of chromosome 5 are
relatively rare in breast cancers (http://cgap.nci.nih.gov/Chromo-
somes/RecurrentAberrations); they target preferentially the 5p15
region (Teixeira et al, 2002). Allelic imbalances have been reported
with gains of 5p in 39% of breast tumour cell lines (Forozan et al,
2000). Losses of 5q (86%) are common in BRCA1-mutated
tumours (Tirkkonen et al, 1997).
Chromosome 8 aberrations are very frequent in breast tumours,
resulting in losses of 8p and gains of 8q (Mertens et al, 1995;
Adeyinka et al, 2000; Davidson et al, 2000; Forozan et al, 2000;
Kyto ¨la ¨ et al, 2000; Ho ¨glund et al, 2001; Rummukainen et al, 2001;
Struski et al, 2002; Teixeira et al, 2002; Ferti et al, 2004; Online
CGH Tumour Database; http://cgap.nci.nih.gov/Chromosomes/
RecurrentAberrations). The 8p11–p21 region contains several
potential TSG and oncogenes (Ade ´laı ¨de et al, 1998, 2003; Ugolini
et al, 1999; Conte et al, 2002; Ray et al, 2004).
We have recently shown by FISH analysis that NRG1 (8p21) is
frequently targeted by recurrent breakpoints in breast tumour cell
lines including ZR-75-1 (Ade ´laı ¨de et al, 2003), and in 6% of
Table 2 Regional localisation of the most frequent breakpoints (43).
Regional
locations
Number of
breakpoints BI RI BI RI ( 10
 2)
1p22.1–p12 7 7/47 6/11 8.12
1q11–q21.2 11 11/47 7/11 14.9
1q21.3–q24 6 6/47 4/11 4.64
1q25–q31 5 5/47 4/11 3.87
1q32.1–q42.2 5 5/47 4/11 3.87
5p13.2–p10 11 11/29 7/10 26.55
5q22–q31.3 9 9/29 7/10 21.72
8p12–p11 8 8/28 5/9 15.87
8q10–q21.1 4 4/28 4/9 6.35
8q22.1–q23 6 6/28 4/9 9.52
8q24.1–qter 6 6/28 4/9 9.52
12p12–p11 6 6/18 5/7 23.81
12q24.1–qter 5 5/18 3/7 11.9
17q21.3–q22 5 5/14 5/8 22.32
BI¼breakpoint incidence; RI¼recurrence index.
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sprimary tumours (Huang et al, 2004). Moreover, studies by
Courtay-Cahen et al (2000), as well as our work (Ade ´laı ¨de et al,
2003, and data not shown), have suggested the frequent presence of
breakpoints located centromeric to NRG1 (Gelsi-Boyer et al,i n
preparation). Thus, all breakpoint found in this region using
mbanding-FISH were confirmed by FISH using BAC clones
showing again that mbanding-FISH is reliable to map breakpoints.
Multiplication of the entire 8q arm and regional amplifications
on 8q are common features in breast cancer (Kallioniemi et al,
1994; Mark et al, 1997). The majority of 8q amplicons encompass
8q24, and comprise the MYC oncogene (8q24.12) (Yokota et al,
1999; Forozan et al, 2000). However, several studies have shown
the presence of other amplicons at 8q21, 8q22–23 and 8q24
(Kallioniemi et al, 1994; Muleris et al, 1994; Fejzo et al, 1998,
Nupponen et al, 1999; Forozan et al, 2000; Seute et al, 2001),
possibly associated with the presence of several common fragile
sites (Hellman et al, 2002).
Reciprocal translocations t(8;12)(q24;p12), t(12;14)(p11;q11)
and t(12;21)(p12;q22) have been reported in breast diseases
(Rohen et al, 1993; see for reviews Petersson et al, 1997; Cavalli
et al, 2001; http://cgap.nci.nih.gov/Chromosomes/RecurrentAber-
rations). The 12p13, 12q12 and 12q24 regions have the highest
frequencies of breaks (Teixeira et al, 2002). In SK-BR-3, the
derivative der(12)t(3;12) has been previously identified by SKY
FISH (Kyto ¨la ¨ et al, 2000). The use of mbanding-FISH contributed
to facilitate the detection of the inversion and finally to
characterise this derivative as del(12)(q24.2)inv(12)(p11q24.2)
t(3;12)(?;p11).
Chromosome 17 is often the target of amplification at q12–21
and q23 (Forozan et al, 2000; Seute et al, 2001), and of unbalanced
translocations (Kyto ¨la ¨ et al, 2000). Among the characterised
chromosomal rearrangements, the BCAS4–BCAS3 fusion tran-
script has been detected only in MCF-7 cells (Ba ¨rlund et al, 2002).
In our study, a dup(17)(q25q21.3) was detected in UACC-812.
In conclusion, mbanding-FISH is a useful approach to localise
recurrent chromosome alterations throughout the genome. How-
ever, the relevance of these alterations to oncogenesis is not
unambiguous. Some breakpoints may be associated to genome
instability and be part of a background of alterations that do not
involve cancer genes. In contrast, some other breakpoints may be
associated to bona fide cancer genes. They may or may not involve
fragile sites (Huebner and Croce, 2001; Richards, 2001; Dhillon
et al, 2003). It is thus likely that we have identified both relevant
and irrelevant alterations. In the case of breaks that occur at 8p12,
we know that some do target potential cancer genes and are found
in tumour samples (Huang et al, 2004). The two cases of break we
studied in greater detail targeted genes with unknown function.
More work is required to determine whether these alterations are
involved in oncogenesis. The identification of regions of breaks
may provide a repertoire of alterations whose study may reveal
interesting candidates.
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